Karyopharm posts endometrial cancer treatment landscape presentation

Karyopharm

Karyopharm

KPTI

0.00
  • Karyopharm published an endometrial cancer treatment landscape update centered on selinexor as an oral XPO1 inhibitor in maintenance therapy.
  • Highlights SIENDO Phase 3 exploratory TP53 wild-type subgroup: median PFS 13.7 months vs 3.7 months; HR 0.41; P=0.002.
  • Reports longer-term follow-up in TP53 wild-type: median PFS 28.4 months vs 5.2 months; HR 0.44; data cutoff April 1, 2024.
  • Details TP53 wild-type/pMMR follow-up: median PFS 39.5 months vs 4.9 months; HR 0.36; data cutoff April 1, 2024.
  • Outlines XPORT-EC-042 Phase 3 trial in TP53 wild-type advanced or recurrent endometrial cancer; topline results expected mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.